EU approval for Merck & Co's Keytruda
This article was originally published in Scrip
Executive Summary
The European Commission has approved Merck & Co's anti-PD1 immune checkpoint therapy Keytruda (pembrolizumab), for the treatment of advanced melanoma in adults.